Kadima Neuropsychiatry Institute specializes in providing advanced treatments for mental health. We are also conducting research to develop innovative new treatments, such as psychedelics.
KADIMA is seeking participants for a clinical study of the
investigational drug BPL-003 (aka 5-MeO-DMT) for Treatment-Resistant Depression (TRD).
The principal investigator at our site is DAVID FEIFEL, MD, Ph.D.
The following survey will assess your current eligibility to participate in this trial. This survey should take approximately 3 minutes to complete.
Please answer as honestly and as completely as possible.
This survey platform is HIPAA-compliant and designed to protect your protected health information (PHI).
Information entered will only be used for the purposes of eligibility assessment by KADIMA Research Staff members.